References
Montastruc F, Bérnard-Laribière A, Noize P et al (2018) Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 74:619–626
US FDA (2005) http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforhealthcareprofessionals/publishealthadvisories/ucm053171.htm The document has been removed from the FDA website. The systematic review is described in: Schneider LS, Dagerman K, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934–43
European Medicines Agency (2008) http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054057.pdf
AEMPS (2008) Antipsicóticos clásicos y aumento de mortalidad en pacientes ancianos con demencia Nota Informativa Ref 2008/19. http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2008/docs/NI_2008-19_antipsicoticos.pdf
Butlletí Groc (2017) Antipsicóticos: mala ciencia, pseudoinnovación, prescripción desbordada y yatrogenia 29:9–18. https://www.icf.uab.cat/assets/pdf/productes/bg/es/bg293-4.16e.pdf
Gilabert-Perramon A, López-Calahorra P, Escoda-Geli N, Salvadó-Trias C (2010) Receta electrónica en Cataluña (Rec@t): una herramienta de salud. Med Clin 134(Suppl 1):49–55
Kaye JA, Bradbury BD, Jick H (2003) Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 56:569–575
Moore TJ, Mattison DR (2017) Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 177:274–275
Marston L, Nazareth I, Petersen I, Walters K, Osborn DPJ (2014) Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 4:e006135
Mirandola M, Andretta M, Corbari L, Sorio A, Nosè M, Barbui C (2006) Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999–2002. Pharmacoepidemiol Drug Saf 15:412–420
Schmedt N, Jobski K, Kollhorst B, Krappweis J, Rüther E, Schink T, Garbe E (2016) Treatment patterns and characteristics of older antipsychotic users in Germany. Int Clin Psychopharmacol 31:159–169
Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, de Ponti F, Garbe E, Schink T, Herings R, Bezemer ID, Sturkenboom MCJM, Trifirò G (2016) Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 82:487–497
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 355:1525–1538
Gjerden P, Bramness JG, Tvete IF, Slørdal L (2017) The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015. Eur J Clin Pharmacol 73:1173–1179
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Asensio, C., Escoda, N., Sabaté, M. et al. Prevalence of use of antipsychotic drugs in the elderly in Catalonia. Eur J Clin Pharmacol 74, 1185–1186 (2018). https://doi.org/10.1007/s00228-018-2469-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2469-6